Type 1 Diabetes – NovoNordisk NN1436-8182

This study compares insulin icodec, an insulin taken once a week to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 1 diabetes. The study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin glargine taken daily.

Inclusion Criteria:

• Diagnosed with type 1 diabetes mellitus greater than or equal to (≥) 1 year before screening.
• Treated with multiple daily insulin injections (daily basal insulin analogue and bolus insulin analogue regimen) ≥ 6 months before screening.
• HbA1c from 7.0-10.0 percentage (%) (53.0-85.8 millimoles per mole (mmol/mol)), both inclusive, at screening confirmed by central laboratory analysis.
• Ability and willingness to adhere to the protocol including performance of self-measured plasma glucose (SMPG) profiles, based on the investigator’s judgement.
• Other criteria may apply

Call us at 248-282-3640 or complete the form and our team will reach out soon to help determine your eligibility.